|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Overall, significantly elevated BC risk was associated with rs2981582, rs1219648, and rs2420946 risk allele when all studies were pooled into the meta-analysis.
|
20364400 |
2010 |
|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We tested gene-environment interactions in 7610 women who developed breast cancer and 10 196 controls without the disease, studying the effects of 12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451, 5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099, TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively collected information about ten established environmental risk factors (age at menarche, parity, age at first birth, breastfeeding, menopausal status, age at menopause, use of hormone replacement therapy, body-mass index, height, and alcohol consumption).
|
20605201 |
2010 |
|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Odds ratios for breast cancer were greatest for FGFR2-rs2981582 and TNRC9-rs3803662 and, for these 2 SNPs, were significantly greater for estrogen receptor (ER)-positive than for ER-negative disease, both in our data and in meta-analyses of all published data (pooled per-allele ORs [95% confidence intervals] for ER-positive vs ER-negative disease: 1.30 [1.26-1.33] vs 1.05 [1.01-1.10] for FGFR2; interaction P < .001; and 1.24 [1.21-1.28] vs 1.12 [1.07-1.17] for TNRC9; interaction P < .001).
|
20664043 |
2010 |
|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We conducted a literature review to identify case-control studies of variants in 4 genes known to affect breast cancer risk: CHEK2*1100delC; multiple variants in BRCA1 and BRCA2; and FGFR2 rs2981582.
|
20299982 |
2010 |
|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The study by Easton et al reported two FGFR2 SNPs, rs2981582 and rs7895676, to be among those most strongly associated with BC risk.
|
19536173 |
2009 |
|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
FGFR2 rs1219648 and rs2981582 genotypes were significantly associated with breast cancer in EA only in estrogen receptor-positive (ER+), progesterone receptor-positive (PR+) and HER2/Neu-negative (HER2-) tumors.
|
19028704 |
2009 |
|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The known breast cancer SNPs rs13281615, rs2981582 and rs3803662 were confirmed as associated with breast cancer risk (P (allelic test) = 1.8 x 10(-2), OR = 1.17; P (allelic test) = 2.2 x 10(-3), OR = 1.22; P (allelic test) = 5.1 x 10(-2), OR = 1.15, respectively) in the West of Ireland cohort.
|
19005751 |
2009 |
|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We genotyped 13 single nucleotide polymorphisms (SNPs) densely covering a 27 kb region within intron 2 of FGFR2 including two SNPs (rs2981582 and rs1219648) significantly associated with breast cancer and a total 40 tagSNPs across 150 kb of the FGFR2 gene.
|
18285324 |
2008 |
|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The minor alleles of SNP rs2981582 and rs889312 were each associated with increased breast cancer risk in BRCA2 mutation carriers (per-allele hazard ratio [HR] = 1.32, 95% CI: 1.20-1.45, p(trend) = 1.7 x 10(-8) and HR = 1.12, 95% CI: 1.02-1.24, p(trend) = 0.02) but not in BRCA1 carriers. rs3803662 was associated with increased breast cancer risk in both BRCA1 and BRCA2 mutation carriers (per-allele HR = 1.13, 95% CI: 1.06-1.20, p(trend) = 5 x 10(-5) in BRCA1 and BRCA2 combined).
|
18355772 |
2008 |
|
rs2981582
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We also noted a correlation between the number of minor alleles of rs2981582 in FGFR2 and the average number of first-degree and second-degree relatives with breast cancer and/or ovarian cancer (P = 0.05).
|
17997823 |
2007 |
|
rs2981582
|
|
A |
0.800 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies novel breast cancer susceptibility loci.
|
17529967 |
2007 |